Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 542

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

Open access
André, Marc P.E., Girinsky, Théodore, Federico, Massimo, Reman, Oumédaly, Fortpied, Catherine, Gotti, Manuel, Casasnovas, Olivier, Brice, Pauline, van der Maazen, Richard, Re, Alessandro, Edeline, Véronique, Fermé, Christophe, van Imhoff, Gustaaf, Merli, Francesco, Bouabdallah, Réda, Sebban, Catherine, Specht, Lena, Stamatoullas, Aspasia, Delarue, Richard, Fiaccadori, Valeria, Bellei, Monica, Raveloarivahy, Tiana, Versari, Annibale, Hutchings, Martin, Meignan, Michel, Raemaekers, John·2017·Journal of Clinical Oncology

Abstract

Purpose: Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early response evaluation with positron emission tomography (PET) scan may improve selection of patients who need reduced or more intensive treatments. Methods: We performed a randomized trial to evaluate treatment adaptation on the basis of early PET (ePET) after two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in previously untreated—according to European Organisation for Research and Treatment of Cancer criteria favorable (F) and unfavorable (U)—stage I and II HL. The standard arm consisted of ABVD followed by involved-node radiotherapy (INRT), regardless of ePET result. In the experimental arm, ePET-negative patients received ABVD only (noninferiority design), whereas ePET-positive patients switched to two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) and INRT (superiority design). Primary end point was progression-free survival (PFS). Results: Of 1,950 randomly assigned patients, 1,925 received an ePET—361 patients (18.8%) were positive. In ePET-positive patients, 5-year PFS improved from 77.4% for standard ABVD + INRT to 90.6% for intensification to BEACOPPesc + INRT (hazard ratio [HR], 0.42; 95% CI, 0.23 to 0.74; P = .002). In ePET-negative patients, 5-year PFS rates in the F group were 99.0% versus 87.1% (HR, 15.8; 95% CI, 3.8 to 66.1) in favor of ABVD + INRT; the U group, 92.1% versus 89.6% (HR, 1.45; 95% CI, 0.8 to 2.5) in favor of ABVD + INRT. For both F and U groups, noninferiority of ABVD only compared with combined modality treatment could not be demonstrated. Conclusion: In stage I and II HL, PET response after two cycles of ABVD allows for early treatment adaptation. When ePET is positive after two cycles of ABVD, switching to BEACOPPesc + INRT significantly improved 5-year PFS. In ePET-negative patients, noninferiority of ABVD only could not be demonstrated: risk of relapse is increased when INRT is omitted, especially in patients in the F group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.68.6394

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 542

Metadata

Authors
André, M. P. E., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., Casasnovas, O., Brice, P., van der Maazen, R., Re, A., Edeline, V., Fermé, C., van Imhoff, G., Merli, F., Bouabdallah, R., Sebban, C., Specht, L., Stamatoullas, A., Delarue, R., Fiaccadori, V., Bellei, M., Raveloarivahy, T., Versari, A., Hutchings, M., Meignan, M., & Raemaekers, J.
Venue
Journal of Clinical Oncology
Published
2017-06-01
Volume
35
Issue
16
Pages
1786-1794
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2596050027
Cited by
542
References
17
FWCI
40.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. https://app.cochat.ai/papers/10.1200/jco.2016.68.6394
The paper
André, M. P. E., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., Casasnovas, O., Brice, P., van der Maazen, R., Re, A., Edeline, V., Fermé, C., van Imhoff, G., Merli, F., Bouabdallah, R., Sebban, C., Specht, L., Stamatoullas, A., Delarue, R., . . . Raemaekers, J. (2017). Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.68.6394

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.